Next Article in Journal
Oxidative Drugs and microRNA: New Opportunities for Cancer Prevention
Previous Article in Journal
Research Progress and Direction of Novel Organelle—Migrasomes
Previous Article in Special Issue
Therapeutic Potential of Naturally Occurring Small Molecules to Target the Wnt/β-Catenin Signaling Pathway in Colorectal Cancer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 15
Issue 1
10.3390/cancers15010135
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Communication

The FDA-Approved Drug Pyrvinium Selectively Targets ER+ Breast Cancer Cells with High INPP4B Expression

by
Samuel J. Rodgers
,
Lisa M. Ooms
† and
Christina A. Mitchell
*,†
Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Cancers 2023, 15(1), 135; https://doi.org/10.3390/cancers15010135
Submission received: 27 October 2022 / Revised: 9 December 2022 / Accepted: 22 December 2022 / Published: 26 December 2022
(This article belongs to the Special Issue Advances in Targeting Wnt Signaling in Cancer)
Browse Figures
Review Reports Versions Notes

Abstract

:

Simple Summary

Wnt/β-catenin signaling is hyperactivated in many human cancers including up to 50% of breast cancers. Although there has been significant progress in developing therapeutics that suppress Wnt/β-catenin signaling, particularly in colon cancer, the repurposing of FDA-approved therapeutics is likely to be a faster and more cost-effective method to target this pathway in human disease. Pyrvinium is an FDA-approved anthelmintic drug used to treat pinworms, which also suppresses Wnt/β-catenin signaling by activating the β-catenin destruction complex protein, CK1α. Here, we demonstrate that breast cancer cells with increased expression of the oncogene INPP4B, a PI3K regulator that promotes Wnt/β-catenin activation, are selectively sensitive to pyrvinium treatment in 2D and 3D culture. Therefore, Wnt inhibition using pyrvinium may be an effective strategy for treating human breast cancers with high INPP4B expression.

Abstract

The majority of breast cancers are estrogen receptor-positive (ER+), and endocrine therapies that suppress ER signaling are the standard-of-care treatment for this subset. However, up to half of all ER+ cancers eventually relapse, highlighting a need for improved clinical therapies. The phosphoinositide phosphatase, INPP4B, is overexpressed in almost half of all ER+ breast cancers, and promotes Wnt/β-catenin signaling, cell proliferation and tumor growth. Here, using cell viability assays, we report that INPP4B overexpression does not affect the sensitivity of ER+ breast cancer cells to standard-of-care treatments including the anti-estrogen 4-hydroxytamoxifen (4-OHT) or the PI3Kα inhibitor alpelisib. Examination of four small molecule Wnt inhibitors revealed that ER+ breast cancer cells with INPP4B overexpression were more sensitive to the FDA-approved drug pyrvinium and a 4-OHT-pyrvinium combination treatment. Using 3D culture models, we demonstrated that pyrvinium selectively reduced the size of INPP4B-overexpressing ER+ breast cancer spheroids in the presence and absence of 4-OHT. These findings suggest that repurposing pyrvinium as a Wnt inhibitor may be an effective therapeutic strategy for human ER+ breast cancers with high INPP4B levels.

1. Introduction

Almost 80% of all breast cancers are estrogen receptor-positive (ER+) [1]. Endocrine therapies such as selective estrogen receptor modulators (SERMs), selective estrogen receptor downregulators (SERDs) or aromatase inhibitors are the standard-of-care treatment for this breast cancer subset, and these therapies have significantly reduced mortality and disease recurrence [2]. However, despite initial high sensitivity to endocrine therapies, up to 50% of ER+ breast cancer patients eventually relapse, and many develop advanced disease that is refractory to subsequent endocrine therapy [3]. This has led to the clinical development of endocrine-based combination therapies such as the SERD, fulvestrant, together with the cyclin dependent kinase 4/6 (CDK4/6) inhibitor palbociclib/PD-0332991, which collectively prolong survival of patients with advanced ER+ breast cancer [4]. However, these treatments are not curative and affected individuals eventually succumb to disease, highlighting a clinical need to further improve therapeutics that target ER+ breast cancer.
The most common genetic event in ER+ breast cancer is mutation of PIK3CA, the gene encoding the p110α catalytic subunit of phosphoinositide 3-kinase alpha (PI3Kα), which occurs in up to 40% of ER+ breast cancers [5,6]. PI3Kα is activated by growth factor stimulation to generate the lipid second messenger, PI(3,4,5)P3, which is hydrolyzed to PI(3,4)P2 by inositol polyphosphate 5-phosphatases. PI(3,4,5)P3 and PI(3,4)P2 activate a number of downstream effectors including the serine/threonine kinase AKT to regulate cell growth, proliferation, survival and migration [7]. The most common PIK3CA mutations, PIK3CAH1047R and PIK3CAE545K, are gain-of-function mutations that promote constitutive PI3Kα activation in the absence of growth factor stimulation and cause de novo murine mammary tumor formation [8,9,10]. For decades, there has been significant interest in the development of therapeutics that target PI3Kα signaling in breast cancer. The PI3Kα inhibitor alpelisib/BYL719 was recently approved to treat patients with advanced PIK3CA-mutant, hormone receptor-positive breast cancer in combination with fulvestrant [11]. The PI3Kα/γ/δ inhibitor, taselisib, in combination with fulvestrant, exhibits clinical benefit for metastatic ER+ breast cancers associated with multiple PIK3CA mutations [12]. However, current PI3K therapies cause significant adverse effects, and breast cancers can develop therapeutic resistance through a variety of mechanisms including acquired PTEN loss or insulin feedback [13,14].
Inositol polyphosphate 4-phosphatase type II (INPP4B) is a dual specificity 4-phosphatase that hydrolyzes PI(3,4)P2 to PI(3)P downstream of PI3Kα signaling [15]. INPP4B was initially identified as a tumor suppressor in ER− basal-like breast cancer that suppresses PI(3,4)P2-mediated AKT signaling [16,17,18]. However, INPP4B paradoxically functions as an oncogene in several cancers, including acute myeloid leukemia (AML) and colon cancer where its overexpression promotes chemoresistance and tumor growth [19,20,21,22]. More recently, INPP4B was identified as a bona fide marker of ER-positivity in human breast cancer [23]. We reported that INPP4B expression is increased in up to 46% of ER+ breast cancer relative to normal breast tissue, correlating with mutant PIK3CA expression [24]. INPP4B overexpression promotes PIK3CA-mutant ER+ breast cancer cell proliferation and tumor growth via activation of Wnt/β-catenin signaling [24], suggesting that INPP4B functions as an oncogene in this context. There are currently no described INPP4B inhibitors available, and given its capacity to function as both a tumor suppressor and oncogene, therapeutically targeting this lipid phosphatase presents a significant clinical challenge. However, cell culture treatment with small molecule Wnt inhibitors that target PORCN or TNK rescued the increased proliferation of INPP4B-overexpressing ER+ breast cancer cells [24], which raises the possibility that ER+ breast cancers with high INPP4B expression may respond to therapies that target the Wnt/β-catenin pathway.
Here, we examined whether increased INPP4B expression alters the sensitivity of ER+ breast cancer cells to current standard-of-care therapies, and investigated the efficacy of Wnt therapeutics. INPP4B overexpression had little effect on the sensitivity of ER+ breast cancer cells to the SERM afimoxifene/4-hydroxytamoxifen (4-OHT) or the PI3Kα inhibitor alpelisib when cells were grown in monolayer cultures. However, INPP4B overexpressing ER+ breast cancer cells were more sensitive than control cells to pyrvinium, an FDA-approved drug that suppresses Wnt/β-catenin signaling, and to 4-OHT-pyrvinium combination treatment. In three-dimensional (3D) culture models, pyrvinium selectively reversed the increased size of INPP4B-overexpressing ER+ breast cancer spheroids in the presence and absence of 4-OHT. Collectively, our findings suggest that repurposing pyrvinium to inhibit Wnt/β-catenin signaling may be an effective strategy to selectively target ER+ breast cancers with high INPP4B expression.

2. Materials and Methods

2.1. Cell Culture

MCF-7 (cat # HTB-22) and T47D (cat # HTB-133) cells were purchased from ATCC. MCF-7 and T47D cells with stable expression of GFP-INPP4B or GFP-vector were generated and validated previously [24,25]. MCF-7 cells were grown in DMEM containing 10% (v/v) FCS, 2 mM L-glutamine, 100 units/mL penicillin, 1% (v/v) streptomycin, and 10 µg/mL insulin. T47D cells were grown in RPMI containing 10% (v/v) FCS, 2 mM L- glutamine, 100 units/mL penicillin, 1% (v/v) streptomycin, and 10 μg/mL insulin. All cells were maintained in a 5% CO2-humidified 37 °C incubator. All aseptic culture techniques were performed in a class II biohazard hood. Cells were routinely tested to confirm the absence of mycoplasma contamination. Cell line authentication was not performed.
For drug treatments, 2.4 × 104 MCF-7 cells or 1.2 × 104 T47D cells were seeded per well in a 48-well plate. The following day, cells were treated with 4-OHT (Selleckchem, cat # S7827), alpelisib (Selleckchem, cat # S2814), LGK-974 (Selleckchem, cat # S7143), PRI-724 (Selleckchem, cat # S8968), pyrvinium (Selleckchem, cat # S5816), celecoxib (Selleckchem, cat # S1261) or the same volume of DMSO as a vehicle control diluted in reduced growth media containing DMEM with 5% (v/v) FCS, 2 mM L-glutamine, 100 units/mL penicillin, 1% (v/v) streptomycin and 5 µg/mL insulin for MCF-7 cells, or RPMI containing 5% (v/v) FCS, 2 mM L- glutamine, 100 units/mL penicillin, 1% (v/v) streptomycin, and 5 μg/mL insulin for T47D cells.

2.2. Cell Viability Assays

Cell viability was assessed using the CellTiter-Glo® 3D Cell Viability Assay (Promega, cat # G9683) according to the manufacturer’s protocol. Briefly, drug treatment media was removed and 100 μL of fresh reduced growth media then 100 μL CellTiter reagent were added to each well. The plate was shaken for 5 min at 500 rpm, then incubated for 30 minutes in the dark. A BMG LABTECH PHERAstar Plus plate reader with PHERAstar version 5.41 and MARS version 3.32 software was used to measure the integrated luminescence signal.

2.3. Hoechst/Propidium Iodide Staining

Drug treatment media was removed and replaced with phenol red-free media containing 1 µg/mL propidium iodide (PI) (Sigma, cat # P4170) and 1 µg/mL Hoechst 33342 (Bio-Rad, cat # 639) for 30 min. Cells were imaged using an Invitrogen EVOS® FL Auto Imaging System with a 10× objective. The percentage of PI-positive cells was determined using the “cell counter” plugin in ImageJ version 2.0.0 software [26].

2.4. Ki67 Immunofluorescence

Approximately 2.4 × 104 MCF-7 cells or 1.2 × 104 T47D cells were seeded per well in a 48-well plate. The following day, cells were treated with reduced growth media containing 4-OHT, pyrvinium or DMSO. After 48 h of treatment, cells were fixed in 4% (w/v) paraformaldehyde (PFA). Cells were washed three times in PBS, then permeabilized for 15 min in PBS containing 0.1% (v/v) Triton X-100. Cells were washed three times in PBS, then were blocked for 1 h in PBS containing 3% (w/v) BSA. Cells were incubated overnight at 4 °C with Ki67 antibodies (ThermoFisher Scientific, cat # RM-9106-S1, 1:200) diluted in PBS containing 3% (w/v) BSA. Cells were washed three times in PBS, then incubated for 1 h with donkey anti-rabbit Alexa Fluor® 555 antibodies (Invitrogen, cat # A-31572, 1:500) and DAPI (Sigma, cat # D9542, 1:1000) diluted in PBS containing 3% (w/v) BSA. Cells were washed three times in PBS, then imaged using an Invitrogen EVOS® M5000 Imaging System with a 10× objective. The percentage of Ki67-positive cells was determined using the “cell counter” plugin in ImageJ version 2.0.0 software.

2.5. RNA Analysis

RNA was extraction was performed using the Isolate II RNA extraction kit (Bioline, cat # BIO-52073) according to the manufacturer’s protocol. RNA concentration was determined using a NanoPhotometer® NP80 spectrophotometer (Implen). cDNA was synthezised from approximately 200 ng of RNA using the iScript gDNA clear cDNA synthesis kit (Bio-Rad, cat # 172-5035) according to the manufacturers’ instructions. qRT-PCR was performed with the QuantiTect SYBR Green PCR Kit (Qiagen, cat # 204143) using a CFX384 Real Time PCR System (Bio-Rad) with DKK1 (Qiagen, Geneglobe ID # QT00009093), LEF1 (Qiagen, Geneglobe ID # QT00021133) or RRN18S (Qiagen, Geneglobe ID # QT00199367) primers, and analyzed using CFX Manager version 3.1 software (Bio-Rad). The relative expression of DKK1 or LEF1 were normalized to the loading control gene RRN18S, and quantified using the ΔΔCT method.

2.6. 3D Spheroid Assays

MCF-7 or T47D cells were seeded in a 48-well plate by resuspending 5000 cells in 25 µL of Matrigel per well, then 400 µL growth media was added to each well. Cells were cultured in growth media for 4 days to allow 3D spheroid formation, then treated with 4-OHT, pyrvinium or the same volume of DMSO as a vehicle control diluted in reduced growth media. After 72 h, 3D spheroids were imaged using an Invitrogen EVOS® FL Auto Imaging System with a 4× objective. The area of the largest 32 spheroids per well was measured using ImageJ version 2.0.0 software.

2.7. Statistics and Reproducibility

Cells were randomly assigned to treatment or control groups. Sample size calculations or blinding were not performed. All experiments were performed three times. Statistical analysis was performed by two-tailed unpaired t test or one-way ANOVA with Tukey post hoc test using Prism software version 7.0 (GraphPad). p values < 0.05 were considered statistically significant.

3. Results

3.1. INPP4B Has Minimal Effect on ER+ Breast Cancer Cell Sensitivity to 4-OHT or Alpelisib in Monolayer Culture

INPP4B enhances the chemoresistance of some cancers including acute myeloid leukemia and colorectal cancer [19,20,21]. As INPP4B expression is increased in PIK3CA-mutant ER+ breast cancers where it promotes cell proliferation and tumor growth [24], we questioned whether INPP4B also affects the sensitivity of ER+ breast cancer cells to standard-of-care therapies. We previously generated and validated MCF-7 and T47D human immortalized PIK3CA-mutant ER+ breast cancer cell lines with stable ectopic GFP-INPP4B overexpression, in order to model the effects of increased INPP4B expression as we described in a subset of ER+ breast tumors [24,25]. Here, we assessed the viability of cells grown in 2D monolayer culture in response to 48 h of treatment with the SERM 4-OHT, an active metabolite of tamoxifen that inhibits estrogen signaling and is a standard-of-care treatment for ER+ breast cancers. 4-OHT treatment reduced GFP-INPP4B and GFP-vector MCF-7 cell viability to a similar extent at concentrations of 10 µM or greater (Figure 1a,b). 4-OHT treatment also impeded GFP-INPP4B and GFP-vector T47D cell viability comparably (Figure 1c,d), suggesting that INPP4B overexpression does not affect ER+ breast cancer cell sensitivity to anti-estrogen therapy.
Combination therapy comprising the SERM fulvestrant and the PI3Kα inhibitor alpelisib was recently approved for advanced ER+ breast cancers that harbor PIK3CA mutations [11]. Thus, we also assessed whether INPP4B overexpression confers sensitivity of PIK3CA-mutant ER+ breast cancer cells to alpelisib. However, GFP-INPP4B expression did not affect MCF-7 or T47D cell viability to alpelisib treatment (Figure 1e–h). Cell viability was also assessed in response to 4-OHT-alpelisib combination treatment to mimic the effects of fulvestrant-alpelisib therapy used clinically. Interestingly, GFP-INPP4B expression modestly reduced MCF-7 cell sensitivity to 4-OHT-alpelisib combination treatment compared to controls (Figure 1i,j). However, no significant difference was observed between GFP-INPP4B and GFP-vector expressing T47D cells under comparable conditions (Figure 1k,l). Altogether, these data indicate that INPP4B has minimal effect on the sensitivity of PIK3CA-mutant ER+ breast cancer cells in monolayer culture to estrogen or PI3Kα-targeted therapies.

3.2. INPP4B Increases ER+ Breast Cancer Cell Sensitivity to Pyrvinium in Monolayer Culture

To determine whether INPP4B overexpressing ER+ breast cancer cells exhibit enhanced sensitivity to Wnt-targeted therapies, four small molecule Wnt inhibitors that target different Wnt pathway components and are clinically approved and/or undergoing clinical trials were evaluated. LGK-974 is a PORCN inhibitor that prevents Wnt ligand acylation and secretion and successfully reduced Wnt signaling in phase I clinical trials in a range of solid tumors including breast cancer [27,28]. PRI-724 disrupts the interaction between β-catenin and CBP and has also completed phase I trials for hepatitis virus-related cirrhosis [29,30]. Celecoxib/SC-58635 is an FDA-approved non-steroidal anti-inflammatory drug (NSAID) that inhibits COX-2, which like several other NSAIDs has also been reported to suppress Wnt/β-catenin signaling [31,32]. Pyrvinium is an FDA-approved anthelmintic drug used to treat pinworms that binds and hyperactivates the β-catenin destruction complex protein CK1α [33]. Here, we examined the effect of these candidate Wnt inhibitors on MCF-7 ER+ breast cancer cell viability after 48 h treatment in monolayer culture, and whether INPP4B expressing cells were more sensitive to these drugs. LGK-974 treatment had little effect on GFP-INPP4B or GFP-vector cell viability even at concentrations of up to 20 µM (Figure 2a,b), whereas PRI-724 treatment reduced the viability of GFP-INPP4B and GFP-vector cells in the low micromolar range (Figure 2c,d). Celecoxib had little effect on GFP-INPP4B and GFP-vector cell viability except at high doses of 50 µM (Figure 2e,f). No difference in viability was observed between GFP-INPP4B and GFP-vector MCF-7 cells following LGK-974, PRI-724 or celecoxib treatment (Figure 2a–f). Interestingly, pyrvinium reduced the viability of GFP-INPP4B and GFP-vector cells at nanomolar concentrations, and INPP4B expression significantly increased sensitivity to pyrvinium (Figure 2g,h). Thus, our analysis reveals that INPP4B overexpressing MCF-7 cells exhibit increased sensitivity to pyrvinium, but not to LGK-974, PRI-724 or celecoxib.
As therapeutics for ER+ breast cancer can be used clinically in combination with endocrine therapy [4,11], we investigated the effect of candidate Wnt inhibitors on cell viability in combination with 4-OHT. Interestingly, 4-OHT-LGK-974 reduced the viability of GFP-INPP4B cells but had little effect on GFP-vector controls (Figure 3a,b). 4-OHT-PRI-724 treatment reduced the viability of both GFP-INPP4B and GFP-vector cells, and GFP-INPP4B cells were significantly more sensitive to this treatment although the effects were modest (Figure 3c,d). GFP-INPP4B and GFP-vector cells exhibited similar sensitivity to 4-OHT-celecoxib treatment (Figure 3e,f). 4-OHT-pyrvinium treatment reduced GFP-INPP4B and GFP-vector cell viability even at very low nanomolar doses of pyrvinium, and importantly, GFP-INPP4B cells were markedly more sensitive (Figure 3g,h). Altogether, these findings suggest that pyrvinium may be a potential drug candidate for ER+ breast cancer cells with high INPP4B expression.
To determine whether pyrvinium treatment affects ER+ breast cancer cell death and/or proliferation, MCF-7 and T47D cells in monolayer culture were co-stained Hoechst/propidium iodide (PI) to detect dying cells (Figure 4), or Ki67 to detect proliferating cells (Figure S1). In the absence of treatment, GFP-INPP4B overexpression had no effect on MCF-7 or T47D cell death, but enhanced T47D cell proliferation. Treatment with 50 nM pyrvinium alone did not induce GFP-INPP4B or GFP-vector expressing MCF-7/T47D cell death. However, GFP-INPP4B expressing MCF-7 cell proliferation was reduced compared to GFP-vector controls under these conditions. Treatment with 10 µM 4-OHT induced cell death and suppressed proliferation of GFP-INPP4B or GFP-vector MCF-7/T47D cells in a similar manner. Combined 4-OHT-pyrvinium treatment had no further effect on MCF-7/T47D cell proliferation, but significantly increased the GFP-INPP4B cell death compared to GFP-vector controls. In control studies, GFP-INPP4B expressing MCF-7 and T47D cells exhibited increased expression of the Wnt target genes DKK1 and LEF1, as previously reported [15], which was significantly reduced after 24 h treatment with 50 nM pyrvinium, confirming inhibition of Wnt signaling (Figure S2). Together, these data identify pyrvinium as a promising Wnt inhibitor for targeting ER+ breast cancers with high INPP4B expression, that is effective at low nanomolar concentrations in combination with 4-OHT.

3.3. Pyrvinium Selectively Reduces the 3D Growth of ER+ Breast Cancer Spheroids with INPP4B Overexpression

Breast cancers grow as 3D tumors where cellular morphology, spatial arrangement of cancer cells and their interaction with the tumor microenvironment impacts on how tumors respond to certain therapies. Although monolayer cancer cell cultures are a valuable experimental model for the rapid screening and evaluation of drug combinations, 3D cancer cell cultures are a superior pre-clinical model of tumor behavior in response to anti-cancer agents [34]. In order to assess whether INPP4B overexpressing ER+ breast cancer cells are sensitive to pyrvinium in 3D culture models, MCF-7 or T47D cells expressing GFP-vector or GFP-INPP4B were cultured in Matrigel for 4 days to form 3D spheroids, then treated with pyrvinium and/or 4-OHT for 72 h (Figure 5). As expected, GFP-INPP4B expressing MCF-7 and T47D cells formed larger spheroids than GFP-vector controls in the absence of pyrvinium or 4-OHT, consistent with increased cell proliferation as previously reported [24]. 4-OHT treatment decreased the size of GFP-vector spheroids but this effect was reduced for GFP-INPP4B spheroids which were significantly larger than 4-OHT-treated GFP-vector spheroids. In contrast, pyrvinium treatment had little effect on GFP-vector spheroids but rescued the increased GFP-INPP4B spheroid size. 4-OHT-pyrvninium treatment had no additive effect over 4-OHT treatment in GFP-vector spheroids, but significantly reduced the size of GFP-INPP4B spheroids to a level similar to 4-OHT-pyrvninium-treated GFP-vector spheroids. Collectively, these findings reveal that ER+ breast cancer cell lines with INPP4B overexpression exhibit increased sensitivity to the FDA-approved Wnt inhibitor pyrvinium or 4-OHT-pyrvinium combination treatment, and thus repurposing pyrvinium may be a therapeutic strategy to consider for this subset of breast cancers.

4. Discussion

INPP4B expression is increased in almost half of all ER+ breast cancers, which promotes cell proliferation and tumor growth via activation of Wnt/β-catenin signaling [24]. There are currently no therapeutics that directly target INPP4B. Here, we identify the FDA-approved Wnt inhibitor pyrvinium as a potential adjunct treatment for ER+ breast cancers with increased INPP4B expression. INPP4B overexpression did not affect the sensitivity of ER+ breast cancer cells in monolayer culture to current standard-of-care therapies including 4-OHT or alpelisib. However, INPP4B-overexpressing ER+ breast cancers cells were more sensitive to pyrvinium treatment when grown in monolayer culture, and combined 4-OHT-pyrvinium treatment significantly enhanced INPP4B-overexpressing ER+ breast cancer cell death. Pyrvinium or 4-OHT-pyrvinium treatment also rescued the increased size of INPP4B-overexpressing ER+ breast cancer 3D spheroids. Therefore, pyrvinium has the potential to be repurposed as a therapeutic for ER+ breast cancers that exhibit increased INPP4B expression.
Wnt/β-catenin signaling is hyperactivated in a range of human cancers including in up to 50% of breast cancers [35]. There has been substantial interest in developing therapeutics that suppress Wnt/β-catenin activation including small molecule inhibitors such as LGK-974 and PRI-724, as well as SFRP peptides and FZD antibodies [36]. However, the clinical progress of Wnt-targeted therapies has been impaired due to intolerable adverse effects, an inability to achieve sufficient Wnt inhibition in patients, and a lack of biomarkers to stratify patients that are more likely to respond to these therapies. Indeed, our results indicate that INPP4B-overexpressing ER+ breast cancers cells exhibit increased sensitivity towards LGK-974 or PRI-724 in combination with 4-OHT, suggesting that combining Wnt therapeutics with an endocrine therapy may be a potential strategy for this breast cancer subset. However, the effects observed in these experiments were modest, and required micromolar concentrations of LGK-974 or PRI-724 that are potentially difficult to achieve in affected individuals, suggesting that the specific Wnt inhibitors examined in this study may not be suitable for clinical translation in this context.
A promising clinical strategy for developing Wnt therapeutics is the repurposing of existing FDA-approved drugs that suppress Wnt signaling, thereby significantly reducing the time and cost of drug development. COX-2 inhibitors are widely used to treat inflammation and provide pain relief, and can suppress Wnt/β-catenin signaling via regulation of prostaglandin E2 (PGE2) [31,37]. Interestingly, our results indicate that MCF-7 cells with or without INPP4B overexpression exhibit little sensitivity towards the COX-2 inhibitor, celecoxib, even at micromolar concentrations. Although studies report that MCF-7 cells are sensitive to COX-2 inhibitors [38,39], others suggest that COX-2 inhibitors have little effect due to negligible COX-2 expression [40], consistent with our observations.
Pyrvinium is an anthelmintic drug that was FDA-approved in the 1950s to treat pinworm infections. More recently, pyrvinium was shown to bind and activate CK1α, a member of the β-catenin destruction complex, and thereby suppresses Wnt/β-catenin signaling [33], Consistent with this, our findings demonstrate that pyrvinium or 4-OHT-pyrvinium treatment selectively reduce the viability of ER+ breast cancer cells with INPP4B overexpression. Importantly, pyrvinium was effective at nanomolar doses and much lower concentrations than LGK-974 or PRI-724. As LGK-974, PRI-724 and pyrvinium all target different components of the Wnt pathway, our data would suggest that INPP4B-overexpressing cells may be more sensitive to CK1α inhibition by pyrvinium compared to PORCN or β-catenin/CBP inhibition by LGK-974 or PRI-724, respectively. As INPP4B promotes ER+ breast cancer cell proliferation and tumor growth via enhanced Wnt/β-catenin signaling [24], we predict that pyrvinium reduces cell viability via Wnt/β-catenin suppression. Indeed, pyrvinium treatment reduced Wnt target gene expression in INPP4B-overexpressing cells indicating inhibition of Wnt/β-catenin signaling. However, as pyrvinium is also reported to disrupt mitochondrial electron transport chain complexes and Hedgehog signaling [41,42,43], we cannot exclude the possibility that inhibition of other pathways may also contribute to the cytotoxicity of pyrvinium in ER+ breast cancer cells. Currently there are no clinical trials for pyrvinium in human breast cancer, but it is noteworthy that pyrvinium exhibited cytotoxic effects towards pancreatic cancer cells and xenograft tumors by inhibiting mitochondria function [44], and is currently undergoing phase I clinical trials in human pancreatic cancers (ClinicalTrials.gov Identifier: NCT05055323). Furthermore, pyrvinium treatment was cytotoxic at nanomolar concentrations to ER−, inflammatory breast cancer cells and stem-like breast cancer cells by inhibiting Wnt/β-catenin and lipid anabolism [45,46,47]. Altogether, these findings suggest that pyrvinium may have therapeutic potential for multiple breast cancer subsets, and should be further evaluated in vivo in combination with current standard-of-care therapies in future studies.

5. Conclusions

INPP4B is a bona fide marker of ER-positivity and exhibits increased expression in up to 46% of ER+ breast cancers where it promotes Wnt-mediated cell proliferation and tumor growth. Here, we show INPP4B overexpression does not affect the sensitivity of ER+ breast cancer cells to current standard-of-care therapies, but results in enhanced sensitivity to the FDA-approved Wnt inhibitor pyrvinium or 4-OHT-pyrvinium combination treatment in monolayer and 3D cultures. These findings raise the possibility that INPP4B could be used as a biomarker to stratify the subset of ER+ breast cancer patients that are likely to respond to adjunct pyrvinium therapy.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cancers15010135/s1, Figure S1: Pyrvinium or 4-OHT treatment suppress ER+ breast cancer cell proliferation, Figure S2: Pyrvinium suppresses Wnt target gene expression in INPP4B-overexpressing ER+ breast cancer cells.

Author Contributions

Conceptualization, all authors.; methodology, L.M.O.; formal analysis, S.J.R.; investigation, S.J.R. and L.M.O.; resources, C.A.M.; writing—original draft preparation, all authors; writing—review and editing, all authors; funding acquisition, L.M.O. and C.A.M. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the National Health and Medical Research Council, grant number APP1104614, and the National Breast Cancer Foundation, grant number IIRS-21-033.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

This study does not include data deposited in external repositories. All data that support the findings of this study are available from the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. DeSantis, C.E.; Ma, J.; Gaudet, M.M.; Newman, L.A.; Miller, K.D.; Goding Sauer, A.; Jemal, A.; Siegel, R.L. Breast cancer statistics, 2019. CA. Cancer J. Clin. 2019, 69, 438–451. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Hanker, A.B.; Sudhan, D.R.; Arteaga, C.L. Overcoming Endocrine Resistance in Breast Cancer. Cancer Cell 2020, 37, 496–513. [Google Scholar] [CrossRef] [PubMed]
  3. Clarke, R.; Tyson, J.J.; Dixon, J.M. Endocrine resistance in breast cancer—An overview and update. Mol. Cell. Endocrinol. 2015, 418 Pt 3, 220–234. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Turner, N.C.; Ro, J.; André, F.; Loi, S.; Verma, S.; Iwata, H.; Harbeck, N.; Loibl, S.; Huang Bartlett, C.; Zhang, K.; et al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N. Engl. J. Med. 2015, 373, 209–219. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Sabine, V.S.; Crozier, C.; Brookes, C.L.; Drake, C.; Piper, T.; van de Velde, C.J.; Hasenburg, A.; Kieback, D.G.; Markopoulos, C.; Dirix, L.; et al. Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study. J. Clin. Oncol. 2014, 32, 2951–2958. [Google Scholar] [CrossRef]
  6. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490, 61–70. [Google Scholar] [CrossRef] [Green Version]
  7. Manning, B.D.; Toker, A. AKT/PKB signaling: Navigating the network. Cell 2017, 169, 381–405. [Google Scholar] [CrossRef] [Green Version]
  8. Meyer, D.S.; Koren, S.; Leroy, C.; Brinkhaus, H.; Muller, U.; Klebba, I.; Muller, M.; Cardiff, R.D.; Bentires-Alj, M. Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047R. Oncogenesis 2013, 2, e74. [Google Scholar] [CrossRef] [Green Version]
  9. Liu, P.; Cheng, H.; Santiago, S.; Raeder, M.; Zhang, F.; Isabella, A.; Yang, J.; Semaan, D.J.; Chen, C.; Fox, E.A.; et al. Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat. Med. 2011, 17, 1116–1120. [Google Scholar] [CrossRef]
  10. Tikoo, A.; Roh, V.; Montgomery, K.G.; Ivetac, I.; Waring, P.; Pelzer, R.; Hare, L.; Shackleton, M.; Humbert, P.; Phillips, W.A. Physiological Levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERα-positive tumors. PLoS ONE 2012, 7, e36924. [Google Scholar] [CrossRef]
  11. Andre, F.; Ciruelos, E.; Rubovszky, G.; Campone, M.; Loibl, S.; Rugo, H.S.; Iwata, H.; Conte, P.; Mayer, I.A.; Kaufman, B.; et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N. Engl. J. Med. 2019, 380, 1929–1940. [Google Scholar] [CrossRef]
  12. Vasan, N.; Razavi, P.; Johnson, J.L.; Shao, H.; Shah, H.; Antoine, A.; Ladewig, E.; Gorelick, A.; Lin, T.Y.; Toska, E.; et al. Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors. Science 2019, 366, 714–723. [Google Scholar] [CrossRef]
  13. Hopkins, B.D.; Pauli, C.; Du, X.; Wang, D.G.; Li, X.; Wu, D.; Amadiume, S.C.; Goncalves, M.D.; Hodakoski, C.; Lundquist, M.R.; et al. Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature 2018, 560, 499–503. [Google Scholar] [CrossRef] [Green Version]
  14. Juric, D.; Castel, P.; Griffith, M.; Griffith, O.L.; Won, H.H.; Ellis, H.; Ebbesen, S.H.; Ainscough, B.J.; Ramu, A.; Iyer, G.; et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor. Nature 2015, 518, 240–244. [Google Scholar] [CrossRef] [Green Version]
  15. Rodgers, S.J.; Ferguson, D.T.; Mitchell, C.A.; Ooms, L.M. Regulation of PI3K effector signalling in cancer by the phosphoinositide phosphatases. Biosci. Rep. 2017, 37. [Google Scholar] [CrossRef] [Green Version]
  16. Gewinner, C.; Wang, Z.C.; Richardson, A.; Teruya-Feldstein, J.; Etemadmoghadam, D.; Bowtell, D.; Barretina, J.; Lin, W.M.; Rameh, L.; Salmena, L.; et al. Evidence that inositol polyphosphate 4-phosphatase type II Is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 2009, 16, 115–125. [Google Scholar] [CrossRef] [Green Version]
  17. Fedele, C.G.; Ooms, L.M.; Ho, M.; Vieusseux, J.; O’Toole, S.A.; Millar, E.K.; Lopez-Knowles, E.; Sriratana, A.; Gurung, R.; Baglietto, L.; et al. Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proc. Natl. Acad. Sci. USA 2010, 107, 22231–22236. [Google Scholar] [CrossRef] [Green Version]
  18. Liu, H.; Paddock, M.N.; Wang, H.; Murphy, C.J.; Geck, R.C.; Navarro, A.J.; Wulf, G.M.; Elemento, O.; Haucke, V.; Cantley, L.C.; et al. The INPP4B tumor suppressor modulates EGFR trafficking and promotes triple negative breast cancer. Cancer Discov. 2020, 8, 1226–1239. [Google Scholar] [CrossRef]
  19. Dzneladze, I.; He, R.; Woolley, J.F.; Son, M.H.; Sharobim, M.H.; Greenberg, S.A.; Gabra, M.; Langlois, C.; Rashid, A.; Hakem, A.; et al. INPP4B overexpression is associated with poor clinical outcome and therapy resistance in acute myeloid leukemia. Leukemia 2015, 29, 1485–1495. [Google Scholar] [CrossRef]
  20. Rijal, S.; Fleming, S.; Cummings, N.; Rynkiewicz, N.K.; Ooms, L.M.; Nguyen, N.Y.; Teh, T.C.; Avery, S.; McManus, J.F.; Papenfuss, A.T.; et al. Inositol polyphosphate 4-phosphatase II (INPP4B) is associated with chemoresistance and poor outcome in AML. Blood 2015, 125, 2815–2824. [Google Scholar] [CrossRef]
  21. Yang, L.; Ding, C.; Tang, W.; Yang, T.; Liu, M.; Wu, H.; Wen, K.; Yao, X.; Feng, J.; Luo, J. INPP4B exerts a dual function in the stemness of colorectal cancer stem-like cells through regulating Sox2 and nanog expression. Carcinogenesis 2020, 41, 78–90. [Google Scholar] [CrossRef] [PubMed]
  22. Guo, S.T.; Chi, M.N.; Yang, R.H.; Guo, X.Y.; Zan, L.K.; Wang, C.Y.; Xi, Y.F.; Jin, L.; Croft, A.; Tseng, H.Y.; et al. INPP4B is an oncogenic regulator in human colon cancer. Oncogene 2015, 35, 3049–3061. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Bouchal, P.; Schubert, O.T.; Faktor, J.; Capkova, L.; Imrichova, H.; Zoufalova, K.; Paralova, V.; Hrstka, R.; Liu, Y.; Ebhardt, H.A.; et al. Breast cancer classification based on proteotypes obtained by SWATH mass spectrometry. Cell Rep. 2019, 28, 832–843. [Google Scholar] [CrossRef] [PubMed]
  24. Rodgers, S.J.; Ooms, L.M.; Oorschot, V.M.J.; Schittenhelm, R.B.; Nguyen, E.V.; Hamila, S.A.; Rynkiewicz, N.; Gurung, R.; Eramo, M.J.; Sriratana, A.; et al. INPP4B promotes PI3Kα-dependent late endosome formation and Wnt/β-catenin signaling in breast cancer. Nat. Commun. 2021, 12, 3140. [Google Scholar] [CrossRef] [PubMed]
  25. Rodgers, S.J.; Jones, E.I.; Arumugam, S.; Hamila, S.A.; Danne, J.; Gurung, R.; Eramo, M.J.; Nanayakkara, R.; Ramm, G.; McGrath, M.J.; et al. Endosome maturation links PI3Kα signaling to lysosome repopulation during basal autophagy. EMBO J. 2022, e110398. [Google Scholar] [CrossRef]
  26. Schneider, C.A.; Rasband, W.S.; Eliceiri, K.W. NIH image to imagej: 25 years of image analysis. Nat. Methods 2012, 9, 671–675. [Google Scholar] [CrossRef]
  27. Liu, J.; Pan, S.; Hsieh, M.H.; Ng, N.; Sun, F.; Wang, T.; Kasibhatla, S.; Schuller, A.G.; Li, A.G.; Cheng, D.; et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc. Natl. Acad. Sci. USA 2013, 110, 20224–20229. [Google Scholar] [CrossRef] [Green Version]
  28. Rodon, J.; Argilés, G.; Connolly, R.M.; Vaishampayan, U.; de Jonge, M.; Garralda, E.; Giannakis, M.; Smith, D.C.; Dobson, J.R.; McLaughlin, M.E.; et al. Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours. Br. J. Cancer 2021, 125, 28–37. [Google Scholar] [CrossRef]
  29. Emami, K.H.; Nguyen, C.; Ma, H.; Kim, D.H.; Jeong, K.W.; Eguchi, M.; Moon, R.T.; Teo, J.L.; Kim, H.Y.; Moon, S.H.; et al. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proc. Natl. Acad. Sci. USA 2004, 101, 12682–12687. [Google Scholar] [CrossRef] [Green Version]
  30. Kimura, K.; Kanto, T.; Shimoda, S.; Harada, K.; Kimura, M.; Nishikawa, K.; Imamura, J.; Ogawa, E.; Saio, M.; Ikura, Y.; et al. Safety, tolerability, and anti-fibrotic efficacy of the CBP/β-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study. EBioMedicine 2022, 80, 104069. [Google Scholar] [CrossRef]
  31. Vallée, A.; Lecarpentier, Y.; Vallée, J.N. Targeting the Canonical WNT/β-Catenin Pathway in Cancer Treatment Using Non-steroidal Anti-Inflammatory Drugs. Cells 2019, 8, 726. [Google Scholar] [CrossRef] [Green Version]
  32. Tuynman, J.B.; Vermeulen, L.; Boon, E.M.; Kemper, K.; Zwinderman, A.H.; Peppelenbosch, M.P.; Richel, D.J. Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer. Cancer Res. 2008, 68, 1213–1220. [Google Scholar] [CrossRef] [Green Version]
  33. Thorne, C.A.; Hanson, A.J.; Schneider, J.; Tahinci, E.; Orton, D.; Cselenyi, C.S.; Jernigan, K.K.; Meyers, K.C.; Hang, B.I.; Waterson, A.G.; et al. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α. Nat. Chem. Biol. 2010, 6, 829–836. [Google Scholar] [CrossRef] [Green Version]
  34. Pinto, B.; Henriques, A.C.; Silva, P.M.A.; Bousbaa, H. Three-Dimensional Spheroids as In Vitro Preclinical Models for Cancer Research. Pharmaceutics 2020, 12, 1186. [Google Scholar] [CrossRef]
  35. Lin, S.Y.; Xia, W.; Wang, J.C.; Kwong, K.Y.; Spohn, B.; Wen, Y.; Pestell, R.G.; Hung, M.C. Beta-catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression. Proc. Natl. Acad. Sci. USA 2000, 97, 4262–4266. [Google Scholar] [CrossRef] [Green Version]
  36. Jung, Y.S.; Park, J.I. Wnt signaling in cancer: Therapeutic targeting of Wnt signaling beyond β-catenin and the destruction complex. Exp. Mol. Med. 2020, 52, 183–191. [Google Scholar] [CrossRef] [Green Version]
  37. Wu, M.; Guan, J.; Li, C.; Gunter, S.; Nusrat, L.; Ng, S.; Dhand, K.; Morshead, C.; Kim, A.; Das, S. Aberrantly activated Cox-2 and Wnt signaling interact to maintain cancer stem cells in glioblastoma. Oncotarget 2017, 8, 82217–82230. [Google Scholar] [CrossRef] [Green Version]
  38. Srinath, P.; Rao, P.N.; Knaus, E.E.; Suresh, M.R. Effect of cyclooxygenase-2 (COX-2) inhibitors on prostate cancer cell proliferation. Anticancer Res. 2003, 23, 3923–3928. [Google Scholar]
  39. Matsumoto, G.; Rahman, M.A.; Muta, M.; Nakamura, T.; Bando, H.; Saji, S.; Tsuruta, K.; Okamoto, A.; Toi, M. DFU, a selective COX-2 inhibitor, suppresses MCF-7 xenograft tumor growth in mice. Oncol. Rep. 2004, 12, 281–285. [Google Scholar] [CrossRef]
  40. Larkins, T.L.; Nowell, M.; Singh, S.; Sanford, G.L. Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression. BMC Cancer 2006, 6, 181. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  41. Ishii, I.; Harada, Y.; Kasahara, T. Reprofiling a classical anthelmintic, pyrvinium pamoate, as an anti-cancer drug targeting mitochondrial respiration. Front. Oncol. 2012, 2, 137. [Google Scholar] [CrossRef] [PubMed]
  42. Tomitsuka, E.; Kita, K.; Esumi, H. An anticancer agent, pyrvinium pamoate inhibits the NADH-fumarate reductase system—A unique mitochondrial energy metabolism in tumour microenvironments. J. Biochem. 2012, 152, 171–183. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Li, B.; Fei, D.L.; Flaveny, C.A.; Dahmane, N.; Baubet, V.; Wang, Z.; Bai, F.; Pei, X.H.; Rodriguez-Blanco, J.; Hang, B.; et al. Pyrvinium attenuates Hedgehog signaling downstream of smoothened. Cancer Res. 2014, 74, 4811–4821. [Google Scholar] [CrossRef] [Green Version]
  44. Schultz, C.W.; McCarthy, G.A.; Nerwal, T.; Nevler, A.; DuHadaway, J.B.; McCoy, M.D.; Jiang, W.; Brown, S.Z.; Goetz, A.; Jain, A.; et al. The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria. Mol. Cancer Ther. 2021, 20, 2166–2176. [Google Scholar] [CrossRef]
  45. Dattilo, R.; Mottini, C.; Camera, E.; Lamolinara, A.; Auslander, N.; Doglioni, G.; Muscolini, M.; Tang, W.; Planque, M.; Ercolani, C.; et al. Pyrvinium Pamoate Induces Death of Triple-Negative Breast Cancer Stem-Like Cells and Reduces Metastases Through Effects on Lipid Anabolism. Cancer Res. 2020, 80, 4087–4102. [Google Scholar] [CrossRef]
  46. Xu, L.; Zhang, L.; Hu, C.; Liang, S.; Fei, X.; Yan, N.; Zhang, Y.; Zhang, F. WNT pathway inhibitor pyrvinium pamoate inhibits the self-renewal and metastasis of breast cancer stem cells. Int. J. Oncol. 2016, 48, 1175–1186. [Google Scholar] [CrossRef] [Green Version]
  47. Xu, W.; Lacerda, L.; Debeb, B.G.; Atkinson, R.L.; Solley, T.N.; Li, L.; Orton, D.; McMurray, J.S.; Hang, B.I.; Lee, E.; et al. The antihelmintic drug pyrvinium pamoate targets aggressive breast cancer. PLoS ONE 2013, 8, e71508. [Google Scholar] [CrossRef]
Cancers 15 00135 g001 550
Figure 1. INPP4B overexpression has minimal effect on ER+ breast cancer sensitivity to 4-OHT or alpelisib in monolayer culture. (a–d) MCF-7 (a,b) or T47D (c,d) cells expressing GFP-vector or GFP-INPP4B were treated with 1–20 µM 4-OHT or DMSO as a vehicle control for 48 h, then cell viability was assessed using CellTiter-Glo® assays. Data represent the relative cell viability normalized to untreated cells (a,c), or plotted as a 4-parameter logistical regression (b,d) ± SD (n = 3 experiments). (e–h) MCF-7 (e,f) or T47D (g,h) cells expressing GFP-vector or GFP-INPP4B were treated with 0.2–10 µM alpelisib or DMSO as a vehicle control for 48 h, then cell viability was assessed using CellTiter-Glo® assays. Data represent the relative cell viability normalized to untreated cells (e,g), or plotted as a 4-parameter logistical regression (f,h) ± SD (n = 3 experiments). (i–l) MCF-7 (i,j) or T47D (k,l) cells expressing GFP-vector or GFP-INPP4B were treated with 10 µM 4-OHT and 0.1–5 µM alpelisib or DMSO as a vehicle control for 48 h, then cell viability was assessed using CellTiter-Glo® assays. Data represent the relative cell viability normalized to untreated cells (i,k), or plotted as a 4-parameter logistical regression normalized to 4-OHT-treated cells (j,l) ± SD (n = 3 experiments). p values were determined by two-tailed unpaired t test of the area under the curve in (b,d,f,h,j,l).
Figure 1. INPP4B overexpression has minimal effect on ER+ breast cancer sensitivity to 4-OHT or alpelisib in monolayer culture. (a–d) MCF-7 (a,b) or T47D (c,d) cells expressing GFP-vector or GFP-INPP4B were treated with 1–20 µM 4-OHT or DMSO as a vehicle control for 48 h, then cell viability was assessed using CellTiter-Glo® assays. Data represent the relative cell viability normalized to untreated cells (a,c), or plotted as a 4-parameter logistical regression (b,d) ± SD (n = 3 experiments). (e–h) MCF-7 (e,f) or T47D (g,h) cells expressing GFP-vector or GFP-INPP4B were treated with 0.2–10 µM alpelisib or DMSO as a vehicle control for 48 h, then cell viability was assessed using CellTiter-Glo® assays. Data represent the relative cell viability normalized to untreated cells (e,g), or plotted as a 4-parameter logistical regression (f,h) ± SD (n = 3 experiments). (i–l) MCF-7 (i,j) or T47D (k,l) cells expressing GFP-vector or GFP-INPP4B were treated with 10 µM 4-OHT and 0.1–5 µM alpelisib or DMSO as a vehicle control for 48 h, then cell viability was assessed using CellTiter-Glo® assays. Data represent the relative cell viability normalized to untreated cells (i,k), or plotted as a 4-parameter logistical regression normalized to 4-OHT-treated cells (j,l) ± SD (n = 3 experiments). p values were determined by two-tailed unpaired t test of the area under the curve in (b,d,f,h,j,l).
Cancers 15 00135 g001
Cancers 15 00135 g002 550
Figure 2. INPP4B-overexpressing MCF-7 cells are more sensitive to pyrvinium in monolayer culture. MCF-7 cells expressing GFP-vector or GFP-INPP4B were treated with 0.5–20 µM LGK-974 (a,b), 0.25–7.5 µM PRI-724 (c,d), 1–50 µM celecoxib (e,f), 10–500 nM pyrvinium (g,h) or DMSO as a vehicle control for 48 h, then cell viability was assessed using CellTiter-Glo® assays. Data represent the relative cell viability normalized to untreated cells (a,c,e,g), or plotted as a 4-parameter logistical regression (b,d,f,h) ± SD (n = 3 experiments). p values were determined by two-tailed unpaired t test of the area under the curve in (b,d,f,g).
Figure 2. INPP4B-overexpressing MCF-7 cells are more sensitive to pyrvinium in monolayer culture. MCF-7 cells expressing GFP-vector or GFP-INPP4B were treated with 0.5–20 µM LGK-974 (a,b), 0.25–7.5 µM PRI-724 (c,d), 1–50 µM celecoxib (e,f), 10–500 nM pyrvinium (g,h) or DMSO as a vehicle control for 48 h, then cell viability was assessed using CellTiter-Glo® assays. Data represent the relative cell viability normalized to untreated cells (a,c,e,g), or plotted as a 4-parameter logistical regression (b,d,f,h) ± SD (n = 3 experiments). p values were determined by two-tailed unpaired t test of the area under the curve in (b,d,f,g).
Cancers 15 00135 g002
Cancers 15 00135 g003 550
Figure 3. INPP4B-overexpressing MCF-7 cells are more sensitive to 4-OHT-pyrvinium combination treatment in monolayer culture. MCF-7 cells expressing GFP-vector or GFP-INPP4B were treated with 10 µM 4-OHT ± 0.5–20 µM LGK-974 (a,b), 0.25–7.5 µM PRI-724 (c,d), 1–50 µM celecoxib (e,f), 10–500 nM pyrvinium (g,h) or DMSO as a vehicle control for 48 h, then cell viability was assessed using CellTiter-Glo® assays. Data represent the relative cell viability normalized to untreated cells (a,c,e,g), or plotted as a 4-parameter logistical regression normalized to 4-OHT-treated cells (b,d,f,h) ± SD (n = 3 experiments). p values were determined by two-tailed unpaired t test of the area under the curve in (b,d,f,g).
Figure 3. INPP4B-overexpressing MCF-7 cells are more sensitive to 4-OHT-pyrvinium combination treatment in monolayer culture. MCF-7 cells expressing GFP-vector or GFP-INPP4B were treated with 10 µM 4-OHT ± 0.5–20 µM LGK-974 (a,b), 0.25–7.5 µM PRI-724 (c,d), 1–50 µM celecoxib (e,f), 10–500 nM pyrvinium (g,h) or DMSO as a vehicle control for 48 h, then cell viability was assessed using CellTiter-Glo® assays. Data represent the relative cell viability normalized to untreated cells (a,c,e,g), or plotted as a 4-parameter logistical regression normalized to 4-OHT-treated cells (b,d,f,h) ± SD (n = 3 experiments). p values were determined by two-tailed unpaired t test of the area under the curve in (b,d,f,g).
Cancers 15 00135 g003
Cancers 15 00135 g004 550
Figure 4. 4-OHT-pyrvinium treatment selectively enhances INPP4B-overexpressing ER+ breast cancer cell death. (a–d) MCF-7 (a,b) or T47D (c,d) cells expressing GFP-vector or GFP-INPP4B were treated with 50 nM pyrvinium and/or 10 µM 4-OHT or DMSO as a vehicle control for 48 h, then incubated with 1 µg/mL propidium iodide (PI) and 1 µg/mL Hoechst 33,342 for 30 min (a,c). Data represent the percentage of PI-positive cells ± SD (n = 3 experiments, >300 cells/experiment) (b,d). Scale bar is 100 µm in a, c. + indicates where treatment was added, and – indicates where no treatment was added. p values were determined by one-way ANOVA with Tukey post hoc test in (b,d).
Figure 4. 4-OHT-pyrvinium treatment selectively enhances INPP4B-overexpressing ER+ breast cancer cell death. (a–d) MCF-7 (a,b) or T47D (c,d) cells expressing GFP-vector or GFP-INPP4B were treated with 50 nM pyrvinium and/or 10 µM 4-OHT or DMSO as a vehicle control for 48 h, then incubated with 1 µg/mL propidium iodide (PI) and 1 µg/mL Hoechst 33,342 for 30 min (a,c). Data represent the percentage of PI-positive cells ± SD (n = 3 experiments, >300 cells/experiment) (b,d). Scale bar is 100 µm in a, c. + indicates where treatment was added, and – indicates where no treatment was added. p values were determined by one-way ANOVA with Tukey post hoc test in (b,d).
Cancers 15 00135 g004
Cancers 15 00135 g005 550
Figure 5. INPP4B-overexpressing ER+ breast cancer spheroids are more sensitive to pyrvinium or 4-OHT-pyrvinium. (a–c) MCF-7 cells expressing GFP-vector or GFP-INPP4B were cultured in Matrigel for 4 days to form 3D spheroids, then treated with 50 nM pyrvinium and/or 10 µM 4-OHT or DMSO as a vehicle control for 72 h. Representative brightfield images of 3D spheroids are shown (a). Data represent the area of the largest 32 spheroids (b), or the relative area of the largest 32 spheroids normalized to untreated cells (c) ± SD (n = 3 experiments). (d–f) T47D cells were cultured in Matrigel for 4 days to form 3D spheroids, then treated with 10 nM pyrvinium ± 5 µM 4-OHT or DMSO as a vehicle control for 72 h. Representative brightfield images of 3D spheroids are shown (d). Data represent the area of the largest 32 spheroids (e), or the relative area of the largest 32 spheroids normalized to untreated cells (f) ± SD (n = 3 experiments). Scale bar is 100 µm in (a,d). + indicates where treatment was added, and – indicates where no treatment was added. p values were determined by one-way ANOVA with Tukey post hoc test in (b,c,e,f).
Figure 5. INPP4B-overexpressing ER+ breast cancer spheroids are more sensitive to pyrvinium or 4-OHT-pyrvinium. (a–c) MCF-7 cells expressing GFP-vector or GFP-INPP4B were cultured in Matrigel for 4 days to form 3D spheroids, then treated with 50 nM pyrvinium and/or 10 µM 4-OHT or DMSO as a vehicle control for 72 h. Representative brightfield images of 3D spheroids are shown (a). Data represent the area of the largest 32 spheroids (b), or the relative area of the largest 32 spheroids normalized to untreated cells (c) ± SD (n = 3 experiments). (d–f) T47D cells were cultured in Matrigel for 4 days to form 3D spheroids, then treated with 10 nM pyrvinium ± 5 µM 4-OHT or DMSO as a vehicle control for 72 h. Representative brightfield images of 3D spheroids are shown (d). Data represent the area of the largest 32 spheroids (e), or the relative area of the largest 32 spheroids normalized to untreated cells (f) ± SD (n = 3 experiments). Scale bar is 100 µm in (a,d). + indicates where treatment was added, and – indicates where no treatment was added. p values were determined by one-way ANOVA with Tukey post hoc test in (b,c,e,f).
Cancers 15 00135 g005
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Rodgers, S.J.; Ooms, L.M.; Mitchell, C.A. The FDA-Approved Drug Pyrvinium Selectively Targets ER+ Breast Cancer Cells with High INPP4B Expression. Cancers 2023, 15, 135. https://doi.org/10.3390/cancers15010135

AMA Style

Rodgers SJ, Ooms LM, Mitchell CA. The FDA-Approved Drug Pyrvinium Selectively Targets ER+ Breast Cancer Cells with High INPP4B Expression. Cancers. 2023; 15(1):135. https://doi.org/10.3390/cancers15010135

Chicago/Turabian Style

Rodgers, Samuel J., Lisa M. Ooms, and Christina A. Mitchell. 2023. "The FDA-Approved Drug Pyrvinium Selectively Targets ER+ Breast Cancer Cells with High INPP4B Expression" Cancers 15, no. 1: 135. https://doi.org/10.3390/cancers15010135

APA Style

Rodgers, S. J., Ooms, L. M., & Mitchell, C. A. (2023). The FDA-Approved Drug Pyrvinium Selectively Targets ER+ Breast Cancer Cells with High INPP4B Expression. Cancers, 15(1), 135. https://doi.org/10.3390/cancers15010135

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop